随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
Implementations have had to develop their own strategies for dealing with this. Firefox initially used a linked-list approach that led to O(n) memory growth proportional to the consumption rate difference. In Cloudflare Workers, we opted to implement a shared buffer model where backpressure is signaled by the slowest consumer rather than the fastest.
，更多细节参见safew官方下载
The number of gallbladder surgeries recorded by NHS England in 2024-25 was at its highest peak in the past decade.
在商业世界里，风险永远不会消失，只会被转移。合伙人模式，本质上就是风险的分摊与下沉。